3:21 PM · 28 September 2020

Inovio’s stock plunged as COVID vaccine trial is put on hold

Inovio Pharmaceuticals (INO.US) stock tumbled 32% after the company announced that the Phase 2/3 clinical trial for its coronavirus vaccine candidate had been halted while it answered additional questions from the Food and Drug Administration. Company is planning to respond to the FDA in October, and then the agency has 30 days to issue its decision about whether the trial can move forward.

Inovio Pharmaceuticals (INO.US) stock launched today’s session with a bearish price gap and is currently testing major resistance at $11.00 per share which is additionally strengthened by 200 MA (red line). If sellers manage to break below it, a downward impulse towards $6.03 per could be launched. On the other hand, once buyers regain control, the resistance at $16.53 per share may be at risk. Source: xStation5

8 September 2026, 5:39 PM

The US is pouring hundreds of millions more into quantum computing. This is only the beginning

8 September 2026, 2:44 PM

US Open: NFP Has Shifted Fed Expectations, and Wall Street Now Awaits Inflation

8 September 2026, 12:58 PM

ASML is picking up pace again.

8 September 2026, 11:37 AM

Novartis shares fall the most since 2020 📉 What is behind the 10% decline?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits